12:00 AM
 | 
Feb 01, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AEG35156: Phase II started

Aegera began an open-label, Hong Kong Phase II trial to evaluate Nexavar sorafenib with or without AEG35156 in 50 patients. ...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >